Evidence map›Paper›PMID 42668797›Full record

ArticleBlood. Red cells & iron2025

crizanlizumab and inclacumab are equally potent inhibitors of cell adhesion in the blood of patients with sickle cell disease.

Tina Rubic-Schneider, Tomasz W Kaminski, David Ledieu, Déborah Garcia, Jeannine Hehlen, Coline Burnet-Merlin, Benjamin Cochin de Billy, Barbara Greutmann, Anthony M DeLise, Tomasz Brzoska and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood. Red cells & iron, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Tina Rubic-SchneiderNovartis BioMedical Research, Basel, Switzerland.
Tomasz W KaminskiVascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA, USA.
David LedieuNovartis BioMedical Research, Basel, Switzerland.
Déborah GarciaNovartis BioMedical Research, Basel, Switzerland.
Jeannine HehlenNovartis BioMedical Research, Basel, Switzerland.
Coline Burnet-MerlinLight Chain Bioscience, Plan-les-Ouates, Switzerland.
Benjamin Cochin de BillyNovartis BioMedical Research, Basel, Switzerland.
Barbara GreutmannNovartis BioMedical Research, Basel, Switzerland.
Anthony M DeLiseNovartis BioMedical Research, East Hanover, NJ, USA.
Tomasz BrzoskaVascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA, USA.
Renee BergeronNovartis BioMedical Research, East Hanover, NJ, USA.
Rikesh K DubeyVascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA, USA.
Tirthadipa Pradhan-SunddVascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA, USA.
Frieder KrӧnerNovartis Pharma AG, Basel, Switzerland.
Mélanie VerneretNovartis Pharma AG, Basel, Switzerland.
Andreas BruederleNovartis Pharma AG, Basel, Switzerland.
Patrick C HinesFunctional Fluidics, Detroit, MI, USA.
Xiufeng GaoFunctional Fluidics, Detroit, MI, USA.
Maya DajeeNovartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
Prithu SunddVascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA, USA.

Funding

Pulmonary arteriole occlusion by platelet-neutrophil micro-emboli in Acute Chest SyndromeR01HL128297 · NHLBI · VERSITI WISCONSIN, INC. · PI SUNDD, PRITHU · 2015 to 2025
$5.4M
Mechanisms of platelet exosome-mediated acute chest syndrome in sickle cell diseaseR01HL141080 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI NEAL, MATTHEW D, NOVELLI, ENRICO M · 2019 to 2022
$3.1M
CD39-carrying extracellular vesicles regulate pulmonary thrombosis in Sickle Cell DiseaseR01HL166345 · NHLBI · VERSITI WISCONSIN, INC. · PI Prithu Sundd · 2023 to 2026
$3.1M
NHLBI NIH HHS R01 HL128297NHLBI NIH HHS R01 HL141080NHLBI NIH HHS R01 HL166345
6 · The paper itself

Abstract

Acute painful vaso-occlusive episodes (VOEs) are the primary reason for emergency department visit by sickle cell disease (SCD) patients and contribute to significant morbidity in SCD. Crizanlizumab, a first-in-class humanized anti-P-selectin IgG2 monoclonal antibody, is approved in more than 40 countries for prevention of VOEs in 16 years or older SCD patients. Inclacumab, a fully human anti-P-selectin IgG4 mAb in clinical development is believed to have stronger affinity to P-selectin and greater maximal inhibition of cell-cell interactions than crizanlizumab. Using

Identifiers

PMID42668797
PMCPMC13525636

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.